TriSalus Life Sciences (TLSI) opened 2026 with Q1 revenue of US$8.9 million and basic EPS of US$0.03, a sharp contrast to the loss of US$0.39 per share on US$9.2 million of revenue in Q1 2025. Over the last year, the company has seen revenue move from US$29.4 million on a trailing basis in Q4 2024 to US$44.9 million in Q1 2026, while trailing EPS remained at a loss of US$1.31 per share, keeping the spotlight firmly on how efficiently that top line is being converted into earnings. Margins are front and center in this release, with investors weighing improving quarterly profitability against a still loss making trailing profile.

See our full analysis for TriSalus Life Sciences.

With the headline numbers on the table, the next step is to see how this mix of revenue expansion and uneven profitability compares with the most common narratives around TriSalus and its long term potential.

Q1 swing to US$1.5m profit vs four loss making quarters

• Q1 2026 net income came in at US$1.5 million on US$8.9 million of revenue, compared with four straight quarters of losses ranging from US$7.6 million to US$41.3 million on revenues between US$8.3 million and US$13.2 million.
• Bulls point out that this move into quarterly profit lines up with their view that margins can improve from an earlier loss position toward positive territory over time. However, trailing 12 month net income is still a loss of US$57.1 million, which keeps the focus on sustainability rather than a single quarter.
  • The bullish narrative expects margins to rise meaningfully, and the step from a quarterly loss of US$9.8 million in Q4 2025 to a profit in Q1 2026 supports that direction. At the same time, the loss across the last four quarters shows that the overall business remains loss making.
  • Analysts in the bullish camp frame this as the start of better operating leverage, while the large trailing loss reminds you that one profitable quarter does not yet match their longer term earnings expectations.

Supporters arguing that Q1 marks an early proof point for the more optimistic case can test that view against a fuller breakdown in the 🐂 TriSalus Life Sciences Bull Case

Twelve month loss of US$57.1m keeps profitability risk front and center

• Across the trailing 12 months to Q1 2026, TriSalus generated US$44.9 million of revenue but reported a net loss of US$57.1 million and trailing basic EPS of US$1.31 loss per share, and it is flagged as unprofitable and forecast to remain unprofitable over the next three years.
• Bears highlight that even with a profitable Q1, the company’s recent history of losses and expectations for ongoing unprofitability challenge any quick turnaround story.
  • The trailing loss of US$57.1 million compares with a quarterly profit of only US$1.5 million, so recent earnings are still dominated by earlier loss making periods rather than the latest result.
  • The analysis that TriSalus is not forecast to reach profitability within the next three years lines up closely with this trailing profile and supports the more cautious stance that sustained losses remain a key risk.

Readers who lean toward the cautious side may want to see how those concerns are laid out in detail in the 🐻 TriSalus Life Sciences Bear Case

DCF fair value and 3.7x P/S sit against ongoing dilution

• The stock trades on a P/S of 3.7x, in line with its peer average but below the US Biotechs average of 9.7x. A DCF fair value of US$33.15 sits far above the current share price of US$2.67 and recent analysis also flags substantial shareholder dilution over the past year.
• Consensus style commentary often points to the gap between the current price and the DCF fair value as a potential upside signal, but the combination of continuing losses and dilution means investors need to weigh valuation metrics against ongoing risk in the income statement.
  • The DCF fair value of US$33.15 is very high compared with the US$2.67 share price, yet the latest trailing 12 month loss of US$57.1 million shows that the business is still consuming capital rather than generating it.
  • The note that shareholders experienced substantial dilution over the past year also matters for anyone focusing on that valuation gap, because any future gains would be spread over a larger share base than in prior periods.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for TriSalus Life Sciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Curious whether the mix of risks and rewards here lines up with your own read of the story? Act now, review the details, and weigh up the 2 key rewards and 3 important warning signs

See What Else Is Out There

TriSalus is still carrying a trailing 12 month loss of US$57.1 million and a history of dilution, so profitability and capital preservation remain clear pressure points.

If you want ideas where recent losses and dilution risks are less of a concern, start comparing companies in the 68 resilient stocks with low risk scores right now and see how that profile feels by contrast.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.